Pharmaceutical Business Review (KC) 20-Aug-08

From Kidney Cancer Resource

Jump to: navigation, search

Go Back To Pharmaceutical Business Review (KC)

NICE rejects new kidney cancer drugs

The National Institute for Health and Clinical Excellence, UK has rejected four kidney cancer treatments for use on the National Health Service on grounds that the drugs are not cost effective, according to PharmaTimes.

The draft guidance issued by the National Institute for Health and Clinical Excellence (NICE), contends that Roche's Avastin (bevacizumab), Bayer's Nexavar (sorafenib), Pfizer's Sutent (sunitinib) and Wyeth's Torisel (temsirolimus) are costly for the treatment of advanced or metastatic renal cell carcinoma.

According to Peter Littlejohns, clinical and public health director at NICE, although the four drugs have the potential to extend progression-free survival by five�six months, the treatment comes at a huge cost of GBP20,000-35,000 per patient per year. The cost per quality adjusted life year (QALY) gained of these treatments is between GBP28,500-90,600 per patient (reported by the manufacturers) and GBP71,500- 171,300 per patient, according to NICE's independent academic group. This cost factor is largely the reason behind NICE's rejection of the drugs.

However, PharmaTimes has quoted Peter Johnson, chief clinician at Cancer Research UK, as saying: "It is often difficult to get unequivocal research data in rarer cancers, such as metastatic kidney cancer, which have a small patient population."

NICE has also announced that it will look into the proposals developed by the drug manufacturers for reducing the cost of the drugs.

To View The Original Article Click Here

Convert This Page to PDF format

Disclaimer

Kidney Cancer Resource (KCR) is not influenced by sponsors. The information contained herein is not intended as a substitute for the advice of an appropriately qualified and licensed physician or other licensed health care provider. The information provided here is for educational and information purposes only. Early accurate Diagnosis (Dx.) saves lives. Please check with a physician if you suspect you are ill, never ignore Symptoms. To help your health care specialist make an accurate Diagnosis please keep notes of dates, times and details of your Symptoms. We are not offering medical advice nor do we consider links, individuals or articles accessed through this site to be offering medical advice.

E&OE - Errors & Omissions Excepted

As much of the information posted on this Web Site for peoples convenience is of a medical or technical nature, and may be a matter of life or death the E&OE is a Disclaimer showing that to the best of our ability information is accurate and correctly written or transcribed. Before acting on information on this site you are responsible for checking it with your relevant medical team. We can not be held responsible for any Errors & Omissions made; nor for information on links and articles provided in good faith.

Personal tools